This review examines current approaches to axillary management in HER2-negative, hormone receptor-positive early breast cancer, with a focus on surgical de-escalation, systemic therapy integration, radiotherapy alternatives, and emerging tools for personalized decision-making. The gene discussed is ERBB2; the disease is breast carcinoma.